PPM ACCESS
Access to the PPM Journal and newsletters is FREE for clinicians.
PAINSCAN LITERATURE REVIEW
Issue 1, Volume 3
Abuse-Deterrent Technologies
14 Articles in this Series
Introduction
The effect of a potentially tamper-resistant oxycodone
Commentary: Why Prescribers Need to Adopt Abuse-Deterrent Opioids
Review: The Impact of Abuse-Deterrent Formulations on Prescribing and Abuse
Abuse-Deterrence Guidance Further Highlights Federal Focus
The Burden of Undiagnosed Opioid Abuse Among the Commercially Insured
Reductions in Reported Deaths Following Introduction of Abuse-Deterrent Oxycodone ER (OxyContin)
Abuse-Deterrent Opioids—Evaluation and Labeling
Generic patches containing fentanyl: abuse deterrent evaluation
FDA Advisory Committee Meetings on Abuse-Deterrent Opioids
Regulatory Update: FDA Takes Additional Abuse-Deterrent Steps
Related: At-Risk Patients and Urine Drug Monitoring
Extended-Release Formulations Enter US Market
Development and Impact of Prescription Opioid ADF Technologies
Trends in Opioid Analgesic Abuse and Mortality in the United States

Related: At-Risk Patients and Urine Drug Monitoring

Providing primary care practitioners with a simple, specific guideline for UDM when prescribing opioids.
2018;Pain;9(1) :97–117

In December 2017, an expert panel led by Argoff, Alford, Fudin, et al, reviewed the existing literature and collaborated on clinical experiences to propose guidelines for implementing urine drug monitoring protocols among patients using opioids to manage chronic pain.

 

Next Article:
Extended-Release Formulations Enter US Market
close X
SHOW MAIN MENU
SHOW SUB MENU